BMS and bluebird bio Report the US FDA's Acceptance of Idecabtagene Vicleucel's BLA for Priority Review to Treat Multiple Myeloma
Shots:
- The US FDA has accepted the PR of BLA for idecabtagene vicleucel to treat adult patients with MM prior treated with at least three therapies including an immunomodulatory agent- a proteasome inhibitor- and an anti-CD38 Ab. The anticipated PDUFA date is Mar 27- 2021
- The BLA is based on a P-II KarMMa study assessing ide-cel in 128 adults with heavily pre-treated and highly refractory MM exposed to three therapies. The results of the study are presented at ASCO20
- Ide-cel is a BCMA directed genetically modified autologous CAR T cell immunotherapy and has received FDA’s BT and EMA’s PRIME designation. BMS plans regulatory submissions for ide-cel in additional markets outside the US and EU
Ref: BMS| Image: BMS
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com